Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

Williams CJ, 1985, J Clin Oncol, 3, 1455, 10.1200/JCO.1985.3.11.1455

10.1016/S0140-6736(84)90594-4

10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J

10.1136/bmj.303.6807.884

Thigpen JT, 1989, Semin Oncol, 16, 58

10.1016/0090-8258(92)90272-K

Williams CJ, 1992, Semin Oncol, 19, 120

Sutton GP, 1989, J Clin Oncol, 7, 223, 10.1200/JCO.1989.7.2.223

McGuire WP, 1989, Ann Intern Med, 111, 273, 10.7326/0003-4819-111-4-273

Thigpen JT, 1994, J Clin Oncol, 12, 1748, 10.1200/JCO.1994.12.9.1748

Rowinsky EK, 1991, J Clin Oncol, 9, 1691

10.1006/gyno.1993.1250

10.1056/NEJM199504133321507

Blessing JA. Design, analysis and interpretation of chemotherapy trials in gynecologic cancer. In: Deppe G, ed. Chemotherapy of gynecologic cancer. 2nd ed. New York: Wiley–Liss, 1990:63-97.

WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.

10.2307/2281868

Mantel N, 1966, Cancer Chemother Rep, 50, 163

Cox DR, 1972, J R Stat Soc [B], 34, 187

10.2307/2280779

Agresti A. Categorical data analysis. New York: John Wiley, 1990.

Rowinsky EK, 1991, J Clin Oncol, 9, 1704, 10.1200/JCO.1991.9.9.1704

Omura GA, 1991, J Clin Oncol, 9, 1138, 10.1200/JCO.1991.9.7.1138

McGuire WP, 1995, J Clin Oncol, 13, 1589, 10.1200/JCO.1995.13.7.1589

Eisenhauer EA, 1994, J Clin Oncol, 12, 2654, 10.1200/JCO.1994.12.12.2654

10.1038/bjc.1993.488